WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION
Date: 19 June 2019
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
Ms Elen Ohov
REGIONAL OFFICE FOR EUROPE
BUREAU RÉGIONAL DE L’EUROPE Adviser
REGIONALBÜRO FÜR EUROPA European Union Affairs and International Co-
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
operation Department
Head office: Ministry of Social Affairs
UN City, Marmorvej 51,
DK-2100 Copenhagen Ø, Denmark
Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 10122 Tallinn
Email:
[email protected]
Website: http://www.euro.who.int
Estonia
Our reference: Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Ms Ohov,
Global survey on sexually transmitted infections progress, 2019
WHO is committed to report on the implementation progress of the Global Health Sector Strategy
on Sexually Transmitted Infections (STIs) 2016–21.
The Global Health Sector Strategy on STIs (resolution WHA69.22) identified milestones for
achievement by 2020. Reporting from Member States on these milestones and country progress in
implementation will be presented at the World Health Assembly 73 in 2020.
We are writing to seek your assistance in providing WHO Regional Office for Europe with
information on STI interventions related to the global STI strategy at country level.
Please find attached the survey questionnaire entitled “Evaluation of the Global STI Strategy:
country STI survey. STI activities assessment at country level.” for submission to the WHO
Regional Office for Europe. All the information will be used to develop the 2020 report to the World
Health Assembly.
Please confirm the receipt of this message and inform us if you have difficulties receiving the
attachment.
We would be grateful if the completed questionnaire is submitted by e-mail to
[email protected]
by 12 July 2019.
Sincerely yours,
Dr Masoud Dara
Acting Director
Communicable Diseases Department
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
Encls:
Questionnaire “Evaluation of the Global STI Strategy: country STI survey. STI activities assessment
at country level.”
Annex 4. Text for inclusion in data collection forms
Copy for information to:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs,
Suur-Ameerika 1, 10129 Tallinn, Estonia
H.E. Mr Andre Pung, Ambassador, Permanent Mission of the Republic of Estonia to the United Nations Office
and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève,
Switzerland
H.E. Mr Märt Volmer, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia,
Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark
Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn,
Estonia
–2–
CPG
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 1/1
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
This questionnaire will take approximately 30 minutes to complete. Thank you for taking the time.
This information is essential for the assessment of interventions and activities that have taken place since the
launching of the Global Strategy on Sexually Transmitted Infections (STI). The information will not only assist
WHO in compiling its report to the World Health Assembly, but also countries themselves to understand
what has been happening around the prevention and control of STI. The questionnaire will give
a high level assessment of STI prevention and control efforts, and identify areas in need of strengthening
to achieve maximum coverage of STI prevention and care activities.
1. Name of Country:
2. Name of Person or Persons Completing this Form:
3. Job titles/description:
1= National STI programme director or manager
2= National HIV programme director or manager
3= National sexual and reproductive health officer or director
4= National programme officer for maternal and child health
5= National disease surveillance coordinator
6= National laboratory surveillance officer or manager
7= WHO country programme officer
8= Other UN agency HIV, STI or sexual and reproductive health officer (UNICEF, UNAIDS, UNFPA)
9= Other
3a) If Other , please specify:
4. Address:
5. Telephone number:
6. Mobile number:
7. E-mail address:
To be completed by Responder (the responder will consolidate the information if more than one person is involved
in the process):
Name:
Signature:
Day Month Year
Date: 2 0 1 9
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 1/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
I - STI strategy
1. Are you familiar with (have a copy or have the link to) the WHO Global Health Sector Strategy
on Sexually Transmitted Infections, 2016-2021?
1= Yes 2= No
2. Does the country have an official National STI Strategy?
1= Yes 2= No (Go to Q3)
2a) When was it last updated? (year)
9999 if Don't know or Data not available
2b) Please provide the WEB link of National STI Strategy:
2b1) Provide WEB Link if Available :
OR
2b2) Check the box if WEB link is Not available:
2c) Is the National STI Strategy/Programme separate from the National HIV Strategy/Programme?
1= Yes, separate
2= No, integrated with HIV strategy
3= Do not have an STI programme
2d) Was the WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016 used
as a reference to develop or to update the National STI Strategy or Programme?
1= Yes 2= No 3= Don't know 4= Data not available
2e) Has your National STI Strategy/Programme been disseminated and how?
1= Yes 2= No, not formally distributed (Go to Q3)
2e1) Posted on website:
1= Yes 2= No (Go to Q2e2)
2e1s) If Yes , please provide the link:
2e2) Email distribution:
1= Yes 2= No (Go to Q2e3)
If Yes , to whom/at what level:
Yes No
2e2a) Sub-national (provinces/states)
2e2b) Districts
2e2c) Clinics
2e2d) Clinicians/care providers
2e2e) NGOs/other organizations
2e3) Hard copies distributed:
1= Yes 2= No (Go to Q2e4)
If Yes , to whom/at what level:
Yes No
2e3a) Sub-national (provinces/states)
2e3b) Districts
2e3c) Clinics
2e3d) Clinicians/care providers
2e3e) NGOs/other organizations
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 2/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
I - STI strategy (Continued )
2e4) Trainings/oral presentations or other forms of face-to-face meetings:
1= Yes 2= No (Go to Q2e5)
If Yes , to whom/at what level:
Yes No
2e4a) Sub-national (provinces/states)
2e4b) Districts
2e4c) Clinics
2e4d) Clinicians/care providers
2e4e) NGOs/other organizations
2e5) Other:
1= Yes 2= No (Go to Q3)
2e5s) If Other= Yes , please provide a short description of the process:
3. Has the WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016 been used
to guide any new or updated STI policies or programmatic activities?
1= Yes 2= No 3= Don't know 4= Data not available
4. Has the WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016 been
disseminated within your country and how?
1= Yes 2= No, not formally distributed (Go to Q5)
4a) Posted on website:
1= Yes 2= No (Go to Q4b)
4as) If Yes , please provide the link:
4b) Email distribution:
1= Yes 2= No (Go to Q4c)
If Yes , to whom/at what level:
Yes No
4b1) Sub-national (provinces/states)
4b2) Districts
4b3) Clinics
4b4) Clinicians/care providers
4b5) NGOs/other organizations
4c) Hard copies distributed:
1= Yes 2= No (Go to Q4d)
If Yes , to whom/at what level:
Yes No
4c1) Sub-national (provinces/states)
4c2) Districts
4c3) Clinics
4c4) Clinicians/care providers
4c5) NGOs/other organizations
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 3/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
I - STI strategy (Continued )
4d) Trainings/oral presentations or other forms of face-to-face meetings:
1= Yes 2= No (Go to Q4e)
If Yes , to whom/at what level:
Yes No
4d1) Sub-national (provinces/states)
4d2) Districts
4d3) Clinics
4d4) Clinicians/care providers
4d5) NGOs/other organizations
4e) Other:
1= Yes 2= No (Go to Q5)
4es) If Other= Yes , please provide a short description of the process:
II - STI treatment guidelines
5. Are you familiar with (have copies or have the links to) the 2016 WHO STI Treatment Guidelines?
Yes No
5a) Neisseria gonorrhoeae (gonorrhoea)
5b) Chlamydia trachomatis (chlamydia)
5c) Herpes simplex virus: (Genital herpes)
5d) Treponema pallidum (syphilis)
6. Does the country have formal national STI treatment guidelines?
1= Yes 2= No (Go to Q6d)
If Q6= Yes, Complete Q6a, Q6b, Q6c and Go to Q7.
If Q6= No, Complete Q6d and Go to Q7.
6a) If Q6= Yes , when was it last updated? (year)
9999 if Don't know or Data not available
6b) If Q6= Yes , were the 2016 WHO STI treatment guidelines used as a reference for the development
or update of the national STI guidelines?
1= Yes 2= No 3= Don't know 4= Data not available
6c) If Q6= Yes , specify which reference documents have been used to develop national STI treatment guidelines?
Yes No
6c1) WHO STI treatment guidelines
6c2) US CDC STD treatment guidelines
6c3) STI treatment guidelines from a neighbour country
6c4) International Union of STI treatment guidelines
6c5) BASHH Guidelines - British Association for Sexual Health and HIV
6c6) Other
6c6s) If Other= Yes , please specify:
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 4/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
II - STI treatment guidelines (Continued )
6d) If Q6= No , specify which documents are used to guide treatment of STIs?
Yes No
6d1) WHO STI treatment guidelines
6d2) US CDC STD treatment guidelines
6d3) STI treatment guidelines from a neighbour country
6d4) International Union of STI treatment guidelines
6d5) BASHH Guidelines - British Association for Sexual Health and HIV
6d6) Other
6d6s) If Other= Yes , please specify:
7. Have any STI treatment guidelines been disseminated in your country and how?
1= Yes 2= No, not formally distributed (Go to Q8)
7a) Posted on website: 1= Yes 2= No (Go to Q7b)
7as) If Yes , please provide the link:
7b) Email distribution: 1= Yes 2= No (Go to Q7c)
If Yes , to whom/at what level:
Yes No
7b1) Sub-national (provinces/states)
7b2) Districts
7b3) Clinics
7b4) Clinicians/care providers
7b5) NGOs/other organizations
7c) Hard copies distributed: 1= Yes 2= No (Go to Q7d)
If Yes , to whom/at what level:
Yes No
7c1) Sub-national (provinces/states)
7c2) Districts
7c3) Clinics
7c4) Clinicians/care providers
7c5) NGOs/other organizations
7d) Trainings/oral presentations or other forms of face-to-face meetings:
1= Yes 2= No (Go to Q7e)
If Yes , to whom/at what level:
Yes No
7d1) Sub-national (provinces/states)
7d2) Districts
7d3) Clinics
7d4) Clinicians/care providers
7d5) NGOs/other organizations
7e) Other: 1= Yes 2= No (Go to Q8)
7es) If Other= Yes , please provide a short description of the process:
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 5/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
III - National STI priorities
8. Please designate the priority level of each of these interventions in your country for STI control and prevention.
Choose one priority level for programme implementation (High, Medium, Low, Not a Priority or Not Done) per intervention:
INTERVENTION HIGH MEDIUM LOW NOT A PRIORITY
OR NOT DONE
8a) Elimination of mother-to-child Transmission
of HIV & syphilis
8b) HPV Vaccine for young women
8c) Condom distribution
8d) STI syndromic management
8e) STI surveillance and monitoring
8f) Antimicrobial resistance monitoring
of gonococcal isolates
8g) STI screening among high-risk
populations of MSM and sex workers
8h) STI screening conducted among persons with HIV
8i) Provision of STI services for adolescents
IV - Location of STI care services
9. Sexually transmitted infection care services are provided in which of the following clinical settings?
Note: Presence of STI care services is defined as presence of a health professional capable of STI management,
including diagnosis (syndromic or etiological), treatment, counseling, and partner management
If Yes , estimated percentage of all
STI care delivered in this setting
Yes No 999 if Don't know or Data not available
9a) Primary care clinics %
9b) Reproductive health clinics %
9c) HIV clinics %
9d) Family planning clinics %
9e) Antenatal/postnatal care clinics %
9f) Specialized STI clinics %
9g) Key population services (MSM, sex workers) %
9h) Adolescent healthcare services %
9i) Prison settings %
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 6/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
V - Surveillance systems
10. Is STI surveillance or monitoring being done in your country?
1= Yes 2= No (Go to Q11)
10a) If Yes , Which surveillance or monitoring elements are included?
Yes No
10a1) Periodic STI prevalence survey among general and high risk populations
10a2) Etiologic assessment of STI syndromes
10a3) STI case reporting
10b) If Q10a3= Yes , which STIs are reported at different levels of the health system?
a- Universal b- STI Clinics c- Sentinel Sites d- Private Sector e- Laboratories
Yes No Yes No Yes No Yes No
10b1) Syndrome: Urethral discharge
10b2) Syndrome: Genital Ulcer Disease
10b3) Syndrome: Vaginal discharge
Yes No
10b4) Etiologies: Syphilis
10b5) Etiologies: Gonorrhoea
10b6) Etiologies: Chlamydia
10b7) Etiologies: Trichomoniasis
10b8) Etiologies: Syphilis in
pregnant women
10c) Is STI surveillance or monitoring integrated within the national health information system (NHIS)?
1= Yes 2= No
10d) Is the surveillance data disaggregated by:
Yes No
10d1) age:
10d2) sex:
10d3) location:
10d4) population:
11. Is the country entering HIV indicators into the UNAIDS Global AIDS Monitoring System?
1= Yes 2= No (Go to Q13)
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 7/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
V - Surveillance systems (Continued )
12. Is the country entering STI indicators into the UNAIDS Global AIDS Monitoring System?
1= Yes (Complete Q12a to Q12h and Go to Q13) 2= No (Go to Q12i)
If Q12= Yes, check which STI indicators are entered into the UNAIDS Global AIDS Monitoring System:
Yes No
12a) Syphilis screening coverage among pregnant women in antenatal care clinics
12b) Syphilis positivity among pregnant women in antenatal care clinics
12c) Syphilis treatment coverage among pregnant women testing positive in
antenatal care clinics
12d) Congenital syphilis case rate
12e) Syphilis screening and positivity in MSM
12f) Syphilis screening and positivity in sex workers
12g) Urethral discharge case rate in men
12h) Gonorrhoea case rate in men
12i) If Q12= No , why?
VI - Elimination of Mother to Child Transmission of HIV and Syphilis
13. Is there a national strategy for the Elimination of Mother-to-Child Transmission of HIV and Syphilis?
1= Yes 2= No (Go to Q14) 3= Yes, but for HIV only (Go to Q14)
13a) If Yes , add and/or provide link to the CS case definition
13b) If Yes, is the country planning to validate elimination of vertical transmission of both HIV and syphilis or
Path to Elimination?
1= Yes 2= No
13c) If Yes, which year is country planning to apply for WHO validation
of elimination (EMTCT) or Path to Elimination? 2 0
99 if Don't know or Data not available
14. Is there a national policy for screening pregnant women for HIV?
1= Yes 2= No (Go to Q15)
14a) If Yes , how many times during the pregnancy?
14b) If Yes, is the country screening at delivery?
1= Yes 2= No
15. Is there a national policy for screening pregnant women for syphilis?
1= Yes 2= No
15a) If Yes , how many times during the pregnancy?
15b) If Yes, is the country screening at delivery?
1= Yes 2= No
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 8/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
VI - Elimination of Mother to Child Transmission of HIV and Syphilis (Continued)
16. Are pregnant women routinely screened for any of the following STIs?
Yes No
16a) HIV
16b) Syphilis
16c) Gonorrhoea
16d) Chlamydia
16e) Trichomoniasis
16f) Human papillomavirus (HPV)
16g) Genital herpes
16h) Hepatitis B
16i) Hepatitis C
16h) Other
16hs) If Other= Yes , please specify:
17. Are rapid syphilis tests used in antenatal care (ANC) clinics?
1= Yes 2= No (Go to Q18)
17a) If your country uses rapid syphilis tests in ANC have you experienced stockouts of test kits?
1= Yes 2= No
18. Are dual HIV/syphilis tests used in antenatal care (ANC) clinics?
1= Yes 2= No (Go to Q19)
18a) If Yes, please specify brand:
18b) If Yes, please specify price:
VII - Screening, Diagnosis, and Treatment of STIs
19. Are key populations of men who have sex with men (MSM) and sex workers screened for any of the following STIs?
1- MSM 2- Sex workers
Yes No Yes No
19a) HIV
19b) Syphilis
19c) Gonorrhoea
19d) Chlamydia
19e) Trichomoniasis
19f) Human papillomavirus (HPV)
19g) Genital herpes
19h) Hepatitis B
19i) Hepatitis C
19j) Other
19js) If Other= Yes , please specify:
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 9/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
VII - Screening, Diagnosis, and Treatment of STIs (Continued)
20. Which of the following diagnostic tests are available for STI diagnosis for the general population?
Yes No
20a) HIV
20b) Syphilis
20c) Gonorrhoea
20d) Chlamydia
20e) Trichomoniasis
20f) Human papillomavirus (HPV)
20g) Genital herpes
20h) Hepatitis B
20i) Hepatitis C
20j) Other
20js) If Other= Yes , please specify:
21. Have any studies been conducted in the country to identify the common etiologies of STI syndromes
(urethral discharge, vaginal discharge, genital ulcer disesase)?
1= Yes 2= No (Go to Q22)
21a) Year of the latest version of the study:
9999 if Don't know or Data not available
21b1) Provide WEB Link if Available :
OR
21b2) Check the box if WEB link is Not available:
22. What are the recommended medications used for urethral discharge?
Yes No
22a) Acyclovir
22b) Azithromycin
22c) Benzathine penicillin
22d) Ceftriaxone
22e) Cefixime
22f) Doxycycline
22g) Metronidazole
22h) Other
22hs) If Other= Yes , please specify:
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 10/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
VII - Screening, Diagnosis, and Treatment of STIs (Continued )
23. What are the recommended medications used for vaginal discharge?
Yes No
23a) Acyclovir
23b) Azithromycin
23c) Benzathine penicillin
23d) Ceftriaxone
23e) Cefixime
23f) Doxycycline
23g) Metronidazole
23h) Other
23hs) If Other= Yes , please specify:
24. What are the recommended medications used for genital ulcer disease?
Yes No
24a) Acyclovir
24b) Azithromycin
24c) Benzathine penicillin
24d) Ceftriaxone
24e) Cefixime
24f) Doxycycline
24g) Metronidazole
24h) Other
24hs) If Other= Yes , please specify:
25. Which medications are on the national formulary or procurement list for treatment of STIs?
Yes No
25a) Acyclovir
25b) Azithromycin
25c) Benzathine penicillin
25d) Ceftriaxone
25e) Cefixime
25f) Doxycycline
25g) Metronidazole
25h) Other
25hs) If Other= Yes , please specify:
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 11/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
VII - Screening, Diagnosis, and Treatment of STIs (Continued )
26. Has the country experienced stockouts of STI medications?
If Yes , year when stockout was identified
(9999 if Don't know or Data not available )
Yes No First identified Last identified
26a) Acyclovir
26b) Azithromycin
26c) Benzathine penicillin
26d) Ceftriaxone
26e) Cefixime
26f) Doxycycline
26g) Metronidazole
26h) Crystalline penicillin
26i) Other
26is) If Other= Yes , please specify:
VIII - Surveillance for Antimicrobial Resistance (AMR) in Gonorrhoea/Gonococcal isolates
27. Is antimicrobial susceptibility testing performed by your national reference lab?
1= Yes 2= No (Go to Q29)
27a) Is antimicrobial susceptibility testing for gonorrhoea performed by your national reference lab?
1= Yes 2= No (Go to Q29)
27as) If Yes , please, provide name of national reference lab:
27b) If Yes, were the results used to inform treatment schemes?
1= Yes 2= No
28. Is surveillance of gonococcal antimicrobial susceptibility conducted in your country?
1= Yes 2= No (Go to Q29)
28a) Year of latest study of susceptibility testing:
9999 if Don't know or Data not available
28b) Name of test method:
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 12/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
IX. HPV vaccination, screening, diagnosis, and treatment
29. Is the human papillomavirus (HPV) vaccine included in the national immunization schedule?
1= Yes 2= No (Go to Q30)
29a) If Q29= Yes , please provide the WEB link of National immunization schedule:
29a1) Provide WEB link if Available :
OR
29a2) Check the box if WEB link is Not available:
29b) If Q29= Yes , to whom and at what age?
29b1) Adolescent girls:
1= Yes 2= No
29b2) Adolescent girls and boys:
1= Yes 2= No
29b3) Age range for HPV vaccine:
99 if Don't know
29b4) Is the human papillomavirus (HPV) vaccine for PLHIV included in the national immunization schedule?
1= Yes 2= No
29b4a) If Yes, what is the age range for PLHIV:
99 if Don't know
29b5) Is the human papillomavirus (HPV) vaccine for MSM included in the national immunization schedule?
1= Yes 2= No
29b5a) If Yes, what is the age range for MSM:
99 if Don't know
30. Does your country have a national cancer registry that includes cervical cancer?
1= Yes 2= No (Go to Q31)
Yes No
30a) Population based
30b) Hospital based
30c) National
30d) Sub-National
31. Is screening for cervical cancer available for general populations of women between the ages of 35 and 55?
1= Yes 2= No (Go to Q33)
AAC
World Health Evaluation of the Global STI Strategy: Country STI Survey Page 13/13
Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019)
PROJECT ID: Date form completed:
A 6 5 9 9 6 Day Month Year
2 0 1 9
Name of Country:
IX. HPV vaccination, screening, diagnosis, and treatment (Continued)
32. If cervical cancer screening is available, which tests are used? Yes No
32a) PAP smear/test
32b) HPV test
32bs) If HPV test=Yes , please provide which HPV test is used:
32c) Acetic acid testing
32d) Visual inspection only
32e) Other
32es) If Other= Yes , please specify:
33. What treatments are used for patients with abnormal cervical screening results (pre-cancerous lesions)?
Yes No
33a) Thermo ablation
33b) Cryotherapy (liquid nitrogen)
33c) Loop Electrosurgical Excision Procedure or conization
33d) Surgical removal with other procedure
33e) Other
33es) If Other= Yes , please specify:
X - Technical assistance
34.Is the country in need to WHO technical assistance?
1= Yes 2= No (Go to Q31)
If Yes , on which areas? Yes No
34a) Development of National STI strategy
34b) Development of National STI treatment guidelines
34c) STI care services
34d) STI surveillance
34e) EMTCT of HIV and syphilis
34f) Screening, diagnosis and treatment
34g) Surveillance in AMR resistance in Gonorrhoea
34h) HPV vaccination, screening, diagnosis and treatment
35.What other technical partners / agencies are supporting you in the STI prevention
and control services, and in which particular area?
36.What is the main source of funding support for implementation of STI-related
prevention and control programmes in country?
(Date and Sign questionnaire)
To be completed by Responder: To be completed by Data Entry Operator:
Name: Name:
Signature: Signature:
Day Month Year Day Month Year
Date: 2 0 1 9 Date: 2 0 1 9
Annex 4. TEXT FOR INCLUSION IN DATA COLLECTION FORMS
Data are the basis for all sound public health actions and the benefits of data sharing are widely
recognized, including scientific and public health benefits. Whenever possible, WHO wishes to
promote the sharing of health data, including but not restricted to surveillance and
epidemiological data.
In this connection, and without prejudice to information sharing and publication pursuant to
legally binding instruments, by providing data to WHO, the [Ministry of Health][other
responsible governmental entity] of [Country]:
Confirms that all data to be supplied to WHO (including but not limited to the types listed in
Annex 3) hereunder have been collected in accordance with applicable national laws, including
data protection laws aimed at protecting the confidentiality of identifiable persons;
Agrees that WHO shall be entitled, subject always to measures to ensure the ethical and secure
use of the data, and subject always to an appropriate acknowledgement of [Country]:
- to publish the data, stripped of any personal identifiers (such data without personal identifiers
being hereinafter referred to as “the Data”) and make the Data available to any interested
party on request (to the extent they have not, or not yet, been published by WHO) on terms
that allow non-commercial, not-for-profit use of the Data for public health purposes (provided
always that publication of the Data shall remain under the control of WHO);
- to use, compile, aggregate, evaluate and analyse the Data and publish and disseminate the
results thereof in conjunction with WHO’s work and in accordance with the Organization’s
policies and practices.
Except where data sharing and publication is required under legally binding instruments (IHR,
WHO Nomenclature Regulations 1967, etc.), the [Ministry of Health][other responsible
governmental entity] of [Country] may in respect of certain data opt out of (any part of) the
above, by notifying WHO thereof in writing at the following address, provided that any such
notification shall clearly identify the data in question and clearly indicate the scope of the opt-
out (in reference to the above), and provided that specific reasons shall be given for the opt
out.
[address]
Saatja: Triin Uusberg <
[email protected]>
Saadetud: 20.06.2019 13:39
Adressaat: Mall Hiet <
[email protected]>
Koopia: Tiina Drell <
[email protected]>
Teema: FW: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893
Manused: STI Questionnaire 2019 - EST.pdf; STI_Questionnaire_en.pdf; Annex_eng.pdf
Palun registreerige ning suunake Tiina Drellile.
Aitäh,
Triin
From: Heli Laarmann <
[email protected]>
Sent: Thursday, June 20, 2019 1:10 PM
To: Triin Uusberg <
[email protected]>; Tiina Drell <
[email protected]>
Cc: Elen Ohov <
[email protected]>
Subject: FW: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893
Tiina, palun korralda vastamine. Kas soovid materjale ka Delta kaudu? Ma ise arvan, et ajaloo huvides
oleks hea, kui see saab ka Delta kaudu edastatud ja sellele seal reageeritud.
Heli
From: Triin Uusberg <
[email protected]>
Sent: Thursday, June 20, 2019 10:07 AM
To: Heli Laarmann <
[email protected]>
Cc: Elen Ohov <
[email protected]>
Subject: FW: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893
Kas tahad ka Delta kaudu saada või vastate niisama?
Triin
From: Olga Fradkina <
[email protected]>
Sent: Wednesday, June 19, 2019 11:15 PM
To: Elen Ohov <
[email protected]>
Cc: Andre Pung <
[email protected]>; Marge Reinap <
[email protected]>; Märt Volmer
<
[email protected]>; Triin Uusberg <
[email protected]>
Subject: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893
Please see the attached correspondence sent from the World Health Organization, Regional
Office for Europe. One or more attachments may be included.
Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de
l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalbüro für Europa
См. прикрепленные письма от Европейского регионального бюро Всемирной организации
здравоохранения (один или несколько прикрепленных файлов).